Overview
Assess quality of life of patients using prolonged oxygen therapy
Description
Adult participants of both sexes with COPD and PID, prolonged oxygen use, will be evaluated after being informed about the study, agreeing and signing the informed consent form. Participants will be randomized to a control group and a group monitored for 90 days. The monitored group will receive a wearable device to monitor vital signs of heart rate and oxygen saturation and the control group will receive a pulse oximeter. Both groups will be monitored through the cell phone application.
Eligibility
Inclusion Criteria:
- Patients with a clinical, radiological and/or anatomopathological diagnosis of COPD and ILD according to the 2020 ATS/JRS/ALAT guidelines;
- Age over 18 years;
- Clinical stability (absence of exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks;
- Patients who are on optimized drug therapy, including long-term home oxygen therapy (LTOT)
- Have a smartphone compatible with the monitoring device;
- Signing of the ICF to participate in the study.
Exclusion Criteria:
- Presence of other concomitant lung diseases;
- Myocardial infarction within four months prior to the start of the study, unstable angina or severe heart disease (NYHA functional class III-IV) and/or decompensated.
- Patients who received a lung transplant during the study
- Living outside the coverage area or moving out of state